Pharmaceutical

Bluejay touts positive data for chronic hepatitis D treatment

The biopharma shared preliminary Phase II data at EASL for its IgG1 monoclonal antibody, BJT-778

Jun 6, 2024 - 04:00
Bluejay touts positive data for chronic hepatitis D treatment
The biopharma shared preliminary Phase II data at EASL for its IgG1 monoclonal antibody, BJT-778
Read the original article

Tags:

Previous Article

Flapping frequency of birds, insects, bats and whales described by universal equ...

Next Article

Scientists push for ‘greener’ drugs in published study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Moderna-Merck mRNA cancer vaccine shows promise in combination with melanoma drug

STAT+: Moderna-Merck mRNA cancer vaccine shows promise ...

Apr 17, 2023

Clinical Dose Companies in Contract Manufacturing for the Pharmaceutical Industry

Clinical Dose Companies in Contract Manufacturing for t...

Oct 10, 2024

Magazine: Advancing islet transplantation for type 1 diabetes

Magazine: Advancing islet transplantation for type 1 di...

Dec 18, 2023